Can a ketogenic diet tame acromegaly hormones?
NCT ID NCT07100587
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a three-week ketogenic diet could improve hormone and metabolic measures in 26 adults with active acromegaly, compared to a Mediterranean diet. Participants followed each diet for three weeks, with a two-week break in between. The main goal was to see changes in IGF-1 levels, along with weight, blood sugar, and inflammation markers.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ketogenic diet and Mediterranean diet
- What this could lead to
- If successful, this could show that a short-term ketogenic diet helps control hormone levels and improve metabolic health in people with acromegaly.
- What could go wrong
- This is a small, early-stage study with only 26 participants and short diet periods. Results may not apply to all patients, and the ketogenic diet can be hard to follow long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
26 people
The number who actually took part.
- Started
-
Jun 2024
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of active acromegaly (elevated IGF-1, GH non-suppressible at OGTT) * Stable medical therapy for ≥ 3 months * BMI 25-40 kg/m² * Informed consent signed Exclusion Criteria: * Type 1 diabetes or insulin-treated type 2 diabetes mellitus * History of ketoacidosis * Active malignancy, decompensated liver/kidney disease * Severe psychiatric disorders or eating disorders * Pregnancy or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acromegaly are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Policlinico Paolo Giaccone
Palermo, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New Long-Acting shot takes aim at Acromegaly's hormone overload
- Can a Once-Monthly shot tame Acromegaly's hormone overdrive?
- Can a Growth-Hormone blocker stay safe in everyday use? a korean study investigates
- Which intubation method works best for acromegaly patients?
- New octreotide pill faces off against current capsule in healthy volunteer study
- New software could improve acromegaly care